OR WAIT null SECS
© 2025 MJH Life Sciences™ , Pharmaceutical Technology - Pharma News and Development Insights. All rights reserved.
PharmTech Group spoke with Andy Burns, vice-president of MDI Business Development at Kindeva, ahead of BIO 2025 to find out what’s new in pulmonary drug delivery.
PharmTech Group spoke with Andy Burns, vice-president of MDI Business Development at Kindeva, about trends he is observing in the pulmonary drug delivery field as part of our preview of the BIO International Convention, which is being held from June 16–19, 2025 in Boston.
According to Burns, sustainability is a focus of a lot of pharmaceutical companies and stakeholders. “A lot of our clients and customers have their own well-developed set of policies and procedures that they wish their partner organizations to subscribe to, and certainly very progressive in Europe and the UK and also in the [United States],” Burns says. “So, sustainability and the impact on supply chains, both within Big Pharma, but also their associated contract manufacturers, is certainly a theme that I've seen developing over the past the past few years.”
Click the video above the watch the interview.
Andy Burns, vice-president of MDI Business Development at Kindeva.
Related Content: